Page 2507 - Hematology_ Basic Principles and Practice ( PDFDrive )

2237.e2 Part XII Hemostasis and Thrombosis

50. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of 73. Belperio PS, Rhew DC: Prevalence and outcomes of anemia in indi-
recombinant human activated protein C for severe sepsis. N Engl J viduals with human immunodeficiency virus: a systematic review of the
Med 344(10):699–709, 2001. literature. Am J Med 116(Suppl 7A):27S–43S, 2004.
51. Goldstein B, Nadel S, Peters M, et al: ENHANCE: results of a global 74. Renner LA, Dicko F, Kouéta F, et al: Anaemia and zidovudine-containing
open-label trial of drotrecogin alfa (activated) in children with severe antiretroviral therapy in paediatric antiretroviral programmes in the
sepsis. Pediatr Crit Care Med 7(3):200–211, 2006. IeDEA Paediatric West African Database to evaluate AIDS. J Int AIDS
52. Belloni G, Ramello P, Salcuni MR, et al: Purpura fulminans during Soc 16:18024, 2013.
meningococcal sepsis treated with drotrecogin alpha: a clinical case. 75. Bunupuradah T, Kariminia A, Chan KC, et al: Incidence and predic-
Minerva Anestesiol 72(4):249–254, 2006. tors of severe anemia in Asian HIV-infected children using first-line
53. Vincent JL, Nadel S, Kutsogiannis DJ, et al: Drotrecogin alfa (acti- antiretroviral therapy. Int J Infect Dis 17(10):e806–e810, 2013.
vated) in patients with severe sepsis presenting with purpura fulminans, 76. Calis JC, van Hensbroek MB, de Haan RJ, et al: HIV-associated
meningitis, or meningococcal disease: a retrospective analysis of anemia in children: a systematic review from a global perspective.
patients enrolled in recent clinical studies. Crit Care 9(4):R331–R343, AIDS 22(10):1099–1112, 2008.
2005. 77. Ellaurie M, Burns ER, Rubinstein A: Hematologic manifestations in
54. Veldman A, Fischer D, Wong FY, et al: Human protein C concen- pediatric HIV infection: severe anemia as a prognostic factor. Am J
trate in the treatment of purpura fulminans: a retrospective analysis Pediatr Hematol Oncol 12(4):449–453, 1990.
of safety and outcome in 94 pediatric patients. Crit Care 14(4):R156, 78. Rheingold SR, Burnham JM, Rutstein R, et al: HIV infection present-
2010. ing as severe autoimmune hemolytic anemia with disseminated intra-
55. Aiuto LT, Barone SR, Cohen PS, et al: Recombinant tissue plasminogen vascular coagulation in an infant. J Pediatr Hematol Oncol 26(1):9–12,
activator restores perfusion in meningococcal purpura fulminans. Crit 2004.
Care Med 25(6):1079–1082, 1997. 79. Rendo P, Freigeiro D, Barboni G, et al: A multicenter randomized
56. Zenz W, Zoehrer B, Levin M, et al: Use of recombinant tissue plas- double-blind trial with recombinant human erythropoietin (rHuEPO)
minogen activator in children with meningococcal purpura fulminans: in anemic HIV-infected children treated with antiretrovirals. Int J
a retrospective study. Crit Care Med 32(8):1777–1780, 2004. Pediatr Hematol Oncol 7:235–239, 2001.
57. Ryan BR, Arkel Y, Walters TR, et al: Acquired symptomatic inhibitors 80. Martí-Carvajal AJ, Solà I: Treatment for anemia in people with AIDS.
of plasma clotting factors in nonhemophilic children. Am J Pediatr Cochrane Database Syst Rev (1):CD004776, 2007.
Hematol Oncol 8(2):144–148, 1986. 81. Ambler KL, Vickars LM, Leger CS, et al: Clinical features, treatment,
58. Siemens HJ, Gutsche S, Bruckner S, et al: Antiphospholipid antibodies and outcome of HIV-associated immune thrombocytopenia in the
in children without and in adults with and without thrombophilia. HAART era. Adv Hematol 2012:910954, 2012.
Thromb Res 98(4):241–247, 2000. 82. Ellaurie M, Burns ER, Bernstein LJ, et al: Thrombocytopenia and
59. Frauenknecht K, Lackner K, von Landenberg P: Antiphospholipid human immunodeficiency virus in children. Pediatrics 82(6):905–908,
antibodies in pediatric patients with prolonged activated partial throm- 1988.
boplastin time during infection. Immunobiology 210(10):799–805, 83. Bussel JB, Haimi JS: Isolated thrombocytopenia in patients infected
2005. with HIV: treatment with intravenous gammaglobulin. Am J Hematol
60. Becton DL, Stine KC: Transient lupus anticoagulants associated with 28(2):79–84, 1988.
hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagu- 84. Kumar P, Gupta RA, Chandra J, et al: Clinical course of children with
lant syndrome. J Pediatr 130(6):998–1000, 1997. HIV associated thrombocytopenia. Indian J Pediatr 79(9):1201–1205,
61. Witmer CM, Steenhoff AP, Shah SS, et al: Mycoplasma pneumoniae, 2012.
splenic infarct, and transient antiphospholipid antibodies: a new 85. Ellaurie M: Thrombocytosis in pediatric HIV infection. Clin Pediatr
association? Pediatrics 119(1):e292–e295, 2007. (Phila) 43(7):627–629, 2004.
62. van Hal S, Senanayake S, Hardiman R: Splenic infarction due to 86. Tighe P, Rimsza LM, Christensen RD, et al: Severe thrombocytopenia
transient antiphospholipid antibodies induced by acute Epstein-Barr in a neonate with congenital HIV infection. J Pediatr 146(3):408–413,
virus infection. J Clin Virol 32:245, 2005. 2005.
63. Weinzierl EP, Arber DA: The differential diagnosis and bone marrow 87. Vastert SJ, Kuis W, Grom AA: Systemic JIA: new development in the
evaluation of new-onset pancytopenia. Am J Clin Pathol 139(1):9–29, understanding of the pathophysiology and therapy. Best Pract Res Clin
2013. Rheumatol 23:655–664, 2009.
64. Rogers MF: HIV/AIDS in infants, children, and adolescents. Pediatr 88. Cazzola M, Ponchio L, de Benedetti F, et al: Defective iron supply for
Clin North Am 47:1–260, 2000. erythropoiesis and adequate endogenous erythropoietin production in
65. Falloon J, Eddy J, Wiener L, et al: Human immunodeficiency virus the anemia associated with systemic-onset juvenile chronic arthritis.
infection in children. J Pediatr 114(1):1–30, 1989. Blood 87(11):4824–4830, 1996.
66. Rakhmanina N, Phelps BR: Pharmacotherapy of pediatric HIV infec- 89. Ferguson BJ, Skikne BS, Simpson KM, et al: Serum transferrin receptor
tion. Pediatr Clin North Am 59(5):1093–1115, 2012. distinguishes the anemia of chronic disease from iron deficiency anemia.
67. Centers for Disease Control and Prevention (CDC): HIV surveillance J Lab Clin Med 119(4):385–390, 1992.
report. Vol. 23: diagnoses of HIV infection in the United States and 90. Aalto K, Honkanen V, Lahdenne P: Iron status during anti-TNF
dependent areas, 2011, Atlanta, GA, 2011, CDC. Available from: therapy in children with juvenile idiopathic arthritis. Clin Rheumatol
<https://www.cdc.gov/hiv/pdf/statistics_2011_hiv_surveillance_ 30(1):115–119, 2011.
report_vol_23.pdf>, (Accessed 28.12.16.) 91. Scopelitis E, Perez M, Biundo JJ, Jr: Leukopenia in Still’s disease. JAMA
68. Guillén S, García San Miguel L, Resino S, et al: Opportunistic infec- 252(17):2450–2452, 1984.
tions and organ-specific diseases in HIV-1-infected children: a cohort 92. de Benedetti F, Brunner HI, Ruperto N, et al: Randomized trial of
study (1990-2006). HIV Med 11(4):245–252, 2010. tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med
69. Laufer M, Scott GB: Medical management of HIV disease in children. 367(25):2385–2395, 2012.
Pediatr Clin North Am 47(1):127–153, 2000. 93. Thompson DM, Pegelow CH, Singsen BH, et al: Neutropenia associ-
70. Agwu AL, Fairlie L: Antiretroviral treatment, management challenges ated with chrysotherapy for juvenile rheumatoid arthritis. J Pediatr
and outcomes in perinatally HIV-infected adolescents. J Int AIDS Soc 93(5):871–875, 1978.
16:18579, 2013. 94. de Benedetti F, Massa M, Robbioni P, et al: Correlation of serum
71. Brichard B, Van der Linden D: Clinical practice treatment of HIV interleukin-6 levels with joint involvement and thrombocytosis in sys-
infection in children. Eur J Pediatr 168(4):387–392, 2009. temic juvenile rheumatoid arthritis. Arthritis Rheum 34(9):1158–1163,
72. Coyle TE: Hematologic complications of human immunodeficiency 1991.
virus infection and the acquired immunodeficiency syndrome. Med 95. Bray VJ, Singleton JD: Disseminated intravascular coagulation in Still’s
Clin North Am 81(2):449–470, 1997. disease. Semin Arthritis Rheum 24(3):222–229, 1994.